Sopharma product categories
Pharmaceuticals ↭ Solutions for hemodialysis ↭ Diagnostic products ↭ Solutions for contact lenses ↭ Food supplements ↭ Cosmetics ↭ Oral cavity solutions
For prolonged treatment of bronchospastic syndrome
Код АТХ: R03CC 13
One tablet contains 0.02 mg clenbuterol hydrochloride.
For prolonged treatment of bronchospastic syndrome in mild and moderate atopic and non-atopic bronchial asthma; strain-induced bronchospasm; in the complex therapy of chronic spastic bronchitis and COPD.
Dosage and administration:
Adults: 0,02 mg orally, morning and evening; Maintenance dose – 0,01 mg 2 times daily. In more serious conditions, 0,04 mg, 2 times daily (morning and evening) should be administered in the first days. The dose should be reduced upon condition improving. In children: 6-12 years –1/2 tablet 2 times daily. Over 12 years –1/2 tablet 2-3 times daily or 1 tablet 2 times daily.
Hypersensitivity to the product; thyrotoxicosis; digitalis intoxication, tachycardia, tachyarrhythmia, hyperthrophic obstructive cardiomyopathy; first trimester of pregnancy.
Beta-blockers antagonize Clenbuterol effects. In concomitant administration with antidiabetics, their dose should be increased due to glycogenolysis stimulation by Clenbuterol. Co-administration with cardiac glycosides, MAO-inhibitors and theophylline may cause heart rhythm disorders.
The effect of Clenbuterol is potentiated by tricyclic antidepressants, some antihistamines and levothyroxin and reduced by some antihypertensive products (guanethidine). Halothane and other halogenated hydrocarbon anesthetics and cyclopropane sensitize myocardium and may potentiate the arrhythmogenic effect of в2- sympathomimetics.
Insomnia, headache, hyperkinesias, psychic disorders, reddening, sweating, tremor and anxiety, excitability, dizziness; the patients with Parkinson’s syndrome may feel increase of tremor and muscle rigidity; palpitations, tachycardia, reduction or, rarely, rise of blood pressure; urine retention; paradoxical bronchospasm which requires immediate discontinuation of therapy. In patients with diabetes mellitus, hyperglycaemia may develop. The manifestation of such adverse reactions requires dose reduction without need of therapy termination, because they fade within 1-2 weeks after therapy initiation. In prolonged administration, tachyphyllaxis to Clenbuterol may be observed, but sensitivity is restored after discontinuation of therapy.
50 tablets of 0,02 mg.
On doctor’s prescription.
Welcome to a wwww.BPG.BG site!
|Have a question? Ask us here!|
Copyright © 2013 - 2014 Bulgarian Pharmaceutical Group Ltd. All rights reserved.